Abstract:Detection of NSCLC at the early stage is a potential means to reduce mortality and morbidity of lung cancer. Development of an accurate, non-invasive, economical, and safe test to detect early stage NSCLC remains a challenge. We explored metabolomics profiling of plasma to discriminate early stage NSCLC cases from Cancer-Free Controls (CFC). Frozen plasma samples collected from 2004 to 2014 from 250 patients with clinical early stage NSCLC (drawn prior to surgical resection) and 250 CFCs were obtained from a provincial biorepository. Samples were thawed, extracted, and analyzed in duplicate by blinded laboratory personnel using non-targeted Ultra High Performance Liquid Chromatography/Quadrupole Time-Of-Flight Mass Spectrometry (UHPLC-QTOF-MS). Individual metabolic entities were identified and quantified using Mass Profiler Professional Software (Agilent Technologies, CA, USA). Analysis was restricted to known human metabolites identified by the Metlin and Human Metabolome databases. Candidate metabolites quantified in less than 20% of samples were dropped; missing values were replaced with one-half of the smallest measurement for each metabolite. Final candidate metabolites were screened for differential abundance (DA) between NSCLC cases and CFCs using: (1) False discovery rate (FDR)-adjusted p-values less than 1% after controlling for age, sex and smoking status in linear regression; (2) <1% change in DA due to covariates; (3) up-regulation in NSCLC. Of the 250 NSCLC Cases, 185 (74%) had adenocarcinoma, 65 (26%) had Squamous Cell Carcinoma; 204 (81.6%) had pathological Stage I/II disease (AJCC 7th ed) and 46 (18.4%) had stage III/IV disease. Median age was 70 (range 46-88) in NSCLC cases and 56 (20-89) in CFCs (p<0.001), and NSCLC cases had more males compared to CFCs (46.4% vs 31.2%, p <0.001). NSCLC patients had a higher proportion of current (27.2% vs 6%) or ex-smokers (64.8% vs 20.8%) compared to CFCs (p<0.001). A total of 1,209 known human metabolites were detected using UHPLC-QTOF-MS technique, of which 676 were present in a minimum of 80% of all samples and were used for modeling. Table 1 lists candidate metabolomics biomarkers strongly upregulated in NSCLC cases versus CFCs which were unaffected by covariates of age, sex, and smoking. A multiple logistic regression model using the top 3 metabolites correctly classified NSCLC case from CFC with an overall accuracy of 93.6% and an area under the curve of 0.975. Metabolomics profiling of plasma represents a potential means to distinguish NSCLC cases from CFCs. Further targeted metabolomics analyses of specific classes of metabolites in larger cohorts are warranted.

Diagnosis of Non-Small Cell Lung Cancer by Rapid Metabolic Fingerprinting of Sputum Samples Using Neutral Desorption Extractive Electrospray Ionization Tandem Mass Spectrometry

Diagnosis of NSCLC on sputum by neutral desorption extractive electrospray ionization tandem mass spectrometry

Lung cancer diagnosis method by detecting metabolic gases of lung cells

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Neutral Desorption Extractive Electrospray Ionization Mass Spectrometry Analysis Sputum for Non-Invasive Lung Adenocarcinoma Detection

Altered Phosphatidylcholines Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer.

Ambient mass spectrometry for fast identification of lung cancer

High-Throughput Salivary Metabolite Profiling on an Ultralow Noise Tip-Enhanced Laser Desorption Ionization Mass Spectrometry Platform for Noninvasive Diagnosis of Early Lung Cancer.

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Application of Metabolomics by UHPLC-MS/MS in Diagnostics and Biomarker Discovery of Non-Small Cell Lung Cancer

Diagnosing lung cancer through metabolic fingerprint based on machine learning

Application of Laser Capture Microdissection and Surface-enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Biomarkers for Early Diagnosis of Lung Adenocarcinoma

Non-Small Cell Lung Cancer Detection and Subtyping by UPLC-HRMS-Based Tissue Metabolomics

High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis

Urine Metabolic Profiling for Rapid Lung Cancer Screening: A Strategy Combining Rh-Doped SrTiO3-Assisted Laser Desorption/Ionization Mass Spectrometry and Machine Learning

Clinical Validation of Metabolite Markers for Early Lung Cancer Detection

P2.11-10 Discovery of Potential Biomarkers That Discriminate Early Stage NSCLC from Controls by Non-Targeted Metabolomics Profiling

LC-MS/MS Based Volatile Organic Compound Biomarkers Analysis for Early Detection of Lung Cancer

Rapid Point-of-Care Exhaled Breath Analysis for Lung Cancer Diagnosis Using a Micro Gas Chromatography System: A Pilot Study

In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging

Serum Untargeted Metabolomics Analyses Reveal Metabolic Alteration of Non-Small Cell Lung Cancer and Refine Cancer Detection in Chinese Population